Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Round 1 statement development was led by the SC and informed by an SLR (PROSPERO ID: CRD420251053598) to identify existing literature on the use of interventional therapies SGLT2is and GLP-1 RAs in adults with CKD and T2D with or without obesity [16]
We recommend you consult an expert to see which one is right for you
The planned cardiovascular outcomes trial will help answer whether this translates to any longer-term risk
W.MarquesT
US$ 25.29
US$ 22.64
US$ 28.13
US$ 26.27
US$ 25.11
US$ 21.98
US$ 28.77
US$ 21.86
US$ 20.36
US$ 22.89
US$ 29.19
US$ 20.55
US$ 23.05
US$ 21.90
